

ASPIRIN USE IMPACTS T CELL TRAFFICKING AND CORRELATES WITH LOWER HIV TARGET CELLS AT THE GENITAL MUCOSA

Monika M Kowatsch, Julius Oyugi, Natasha Hollett, Joshua Kimani, Julie Lajoie and Keith R Fowke

The authors do not have conflict of interest to declare


To contact the author: Julie.Lajoie@umanitoba.ca





Introduction

- In Africa, women are twice as likely as men to be infected by HIV during unprotected vaginal intercourse.
- Despite being at high risk of HIV infection, some individuals remain HIV negative (HESN).
- We have associated this natural protection to HIV with a unique immune phenotype called Immune Quiescence. This is defined by a lower level of baseline T cell immune activation, lower level of inflammatory cytokines at the genital tract, and higher level of regulatory T cells in the blood (Card and al, 2013).



- To mimic this unique immune phenotype among susceptible women, we gave a daily dose of aspirin (81mg) to healthy women.
- Aspirin (ASA):
 - Non-steroidal anti-inflammatory drug;
 - Use daily for the prevention of cardiac diseases
 - Widely accessible, safe record, affordable and community accepted .
- In a pilot study, we showed that daily use of ASA, results in a 39% decrease in the proportion of HIV target cells at the female genital tract.

Gap in knowledge:

Is the decrease of genital HIV target cells observed among those taking aspirin is due to a local decrease of immune activation or changes in cell trafficking?

Methods and Participants' Description

Hypothesis: Daily use of ASA will decreased the trafficking of activated T cell at the female genital tract.


Study design:

- Thirty-six HIV uninfected women were enrolled for this study.
- Participants were asked to take 81mg of ASA each day for six weeks.
- Blood was taken at baseline (Visit 1 V1) and six weeks later (Visit 3 V3).
- Flow cytometry was performed on PBMC.
- Trafficking markers measured: CCR5 (for migration to genital mucosa), CXCR3 (for tissue and lung), CD103 (general tracking to mucosa), CCR6 (gut), CD25 (activation), CD29 (β1).

Sociodemographic characteristics of the participants

General Characteristics	
Age (mean [SD])	32 [8.0]
Douching (n(%))	21 (55.3)
Contraception	
No Hormonal Contraception (n(%))	12 (31.6)
Depot/DMPA (n(%))	21 (55.3)
Oral HC (n(%))	2 (5.2)
Regular Partner	
Yes (n(%))	30 (78.9)
No (n(%))	4 (10.5)
Not Disclosed (n(%))	4 (10.5)
Times sexual intercourse with regular partner in last 7 days (mean [SD])	1.19 [1.1]
Used condom with regular partner in the last 7 days (n(%))	5 (13.2)

Results



- After 6 weeks on ASA we observed lower proportion of CD4+ T cells expressing CCR6 and CD4+ T cells expressing CXCR3 in the blood.
- The level of CCR6 expressed per CD4+ T cells was **lower** after ASA uptake compared to baseline.
- We did not observed changes in the proportion of CD4+ T cells expressing CCR5 and CD103 in the blood.
- Proportion of Th17 expressing CCR6 was similar between visits.

Discussion/Conclusion

- CCR6 is an important marker for Th17 and Treg activation during inflammation. ASA use was associated with a decreased in bulk CD4+ CCR6+ cells but did not affect the Th17 cells expressing CCR6.
- CCR6 is also a marker for activated T cells to migrate to the gut. ASA use was associated with a decrease in the proportion of activated T cells that can migrate to the gut mucosa.
- ASA use was associated with a decrease in the proportion of CD4+ expressing CXCR3. CXCR3 is highly expressed on activated Th1 cells and lead to migration of activated T cells to inflamed peripherical tissues and re-entry to lymph node.

- ASA use was associated with a decrease in the trafficking of activated T cells to mucosa.
- ASA use is associated with a lower proportion of HIV target cells at the mucosa.

Thank you!

- Fowke lab member
- Baba Dogo and Pumwani staff
- Ken Oduor
- Geneviève Boily-Larouche
- Lucy Mwangi
- UNITID lab staff
- BIG THANK YOU TO THE PARTICIPANTS



